<DOC>
	<DOCNO>NCT00883623</DOCNO>
	<brief_summary>The treatment oral melphalan prednisone recommend standard treatment AL amyloidosis result rather disappointing . Another therapeutic option pulse high-dose dexamethasone + melphalan ( Mel-Dex ) encourage result regard achievement faster disease response high rate haematological remission . In last 5 - 10 year , promise treatment outcome therapy high-dose melphalan autologous stem cell support report several group highly select patient eligible treatment . Lenalidomide show effective phase II III trial MM patient . Because relationship MM , Lenalidomide promise therapeutic option also patient AL amyloidosis . The addition Lenalidomide Mel-Dex could improve rate complete response ( CR ) organ response patient eligible refuse high-dose chemotherapy .</brief_summary>
	<brief_title>A Trial Treatment With Lenalidomide-Melphalan-Dexamethasone Patients With Primary ( AL ) Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Biopsy proven systemic untreated AL amyloidosis require systemic chemotherapy Not eligible refuse HDM Measurable plasma cell disease Life expectancy &gt; 3 month WHO performance status &lt; 3 NYHA &lt; stage IV Understand voluntarily sign informed consent form Laboratory test result within range Absolute neutrophil count &gt; 1.5 x 109/L Platelet count &gt; 100 x 109/L Creatinine Clearance / MDRD &gt; 40 ml/min Total bilirubin &gt; 2,5 mg/dL Females childbearing potential ( FCBP ) must agree use two reliable form contraception simultaneously practice complete abstinence heterosexual intercourse follow time period relate study : 1 ) least 28 day start study drug ; 2 ) participate study ; 3 ) least 28 day discontinuation study . Multiple Myeloma stage II III ( Durie Salmon ) Previous organ transplantation Not able visit Amyloid Clinic Heidelberg per month Refusal aspiration 100 ml bone marrow study inclusion Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Use experimental drug therapy within 28 day baseline . Known hypersensitivity thalidomide . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . Any prior use lenalidomide . Concurrent use anticancer agent treatment . Known positive HIV infectious hepatitis , B C. Patients depend position Sponsor Principal Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>AL-Amyloidosis</keyword>
	<keyword>Lenalidomide</keyword>
</DOC>